One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Q3 2025 Management View CEO Reshma Kewalramani highlighted "Vertex delivered strong performance across the board in Q3 with ...
Zacks Investment Research on MSN
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...
The medication, trademarked JOURNAVX, offers opioid-like relief without the same risk of addiction. It has been accepted as a ...
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform ...
Their combined market capitalisation rose 4% from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025.
Q. Journavx works for me! I rarely need an opioid like Norco (hydrocodone and acetaminophen) or an NSAID like Celebrex when I’m on it. Now my pain specialist says it is limited to three months a year.
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of ...
The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback